New perspectives in the treatment of body dysmorphic disorder

Eric Hollander, Kevin Hong, Vera Nezgovorova

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Body dysmorphic disorder (BDD) is a disabling illness with a high worldwide prevalence. Patients demonstrate a debilitating preoccupation with one or more perceived defects, often marked by poor insight or delusional convictions. Multiple studies have suggested that selective serotonin reuptake inhibitors and various cognitive behavioral therapy modalities are effective first-line treatments in decreasing BDD severity, relieving depressive symptoms, restoring insight, and increasing quality of life. Selective serotonin reuptake inhibitors have also recently been shown to be effective for relapse prevention. This review provides a comprehensive summary of the current understanding of BDD, including its clinical features, epidemiology, genetics, and current treatment modalities. Additional research is needed to fully elucidate the relationship between BDD and comorbid illnesses such as obsessive-compulsive-related disorders and depression and to develop therapies for refractory patients and those who have contraindications for pharmacological intervention.

Original languageEnglish (US)
Article number361
JournalF1000Research
Volume7
DOIs
StatePublished - Jan 1 2018

Fingerprint

Body Dysmorphic Disorders
Serotonin Uptake Inhibitors
Refractory materials
Depression
Defects
Molecular Epidemiology
Obsessive-Compulsive Disorder
Cognitive Therapy
Therapeutics
Secondary Prevention
Quality of Life
Pharmacology
Research

Keywords

  • BDD
  • Body dysmorphic disorder
  • CBT
  • Cognitve behavioral therapy
  • TMS
  • Transcranial magnetic stimulation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

New perspectives in the treatment of body dysmorphic disorder. / Hollander, Eric; Hong, Kevin; Nezgovorova, Vera.

In: F1000Research, Vol. 7, 361, 01.01.2018.

Research output: Contribution to journalReview article

Hollander, Eric ; Hong, Kevin ; Nezgovorova, Vera. / New perspectives in the treatment of body dysmorphic disorder. In: F1000Research. 2018 ; Vol. 7.
@article{2234236121cb4949bb49e1474f5fa51f,
title = "New perspectives in the treatment of body dysmorphic disorder",
abstract = "Body dysmorphic disorder (BDD) is a disabling illness with a high worldwide prevalence. Patients demonstrate a debilitating preoccupation with one or more perceived defects, often marked by poor insight or delusional convictions. Multiple studies have suggested that selective serotonin reuptake inhibitors and various cognitive behavioral therapy modalities are effective first-line treatments in decreasing BDD severity, relieving depressive symptoms, restoring insight, and increasing quality of life. Selective serotonin reuptake inhibitors have also recently been shown to be effective for relapse prevention. This review provides a comprehensive summary of the current understanding of BDD, including its clinical features, epidemiology, genetics, and current treatment modalities. Additional research is needed to fully elucidate the relationship between BDD and comorbid illnesses such as obsessive-compulsive-related disorders and depression and to develop therapies for refractory patients and those who have contraindications for pharmacological intervention.",
keywords = "BDD, Body dysmorphic disorder, CBT, Cognitve behavioral therapy, TMS, Transcranial magnetic stimulation",
author = "Eric Hollander and Kevin Hong and Vera Nezgovorova",
year = "2018",
month = "1",
day = "1",
doi = "10.12688/f1000research.13700.1",
language = "English (US)",
volume = "7",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - New perspectives in the treatment of body dysmorphic disorder

AU - Hollander, Eric

AU - Hong, Kevin

AU - Nezgovorova, Vera

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Body dysmorphic disorder (BDD) is a disabling illness with a high worldwide prevalence. Patients demonstrate a debilitating preoccupation with one or more perceived defects, often marked by poor insight or delusional convictions. Multiple studies have suggested that selective serotonin reuptake inhibitors and various cognitive behavioral therapy modalities are effective first-line treatments in decreasing BDD severity, relieving depressive symptoms, restoring insight, and increasing quality of life. Selective serotonin reuptake inhibitors have also recently been shown to be effective for relapse prevention. This review provides a comprehensive summary of the current understanding of BDD, including its clinical features, epidemiology, genetics, and current treatment modalities. Additional research is needed to fully elucidate the relationship between BDD and comorbid illnesses such as obsessive-compulsive-related disorders and depression and to develop therapies for refractory patients and those who have contraindications for pharmacological intervention.

AB - Body dysmorphic disorder (BDD) is a disabling illness with a high worldwide prevalence. Patients demonstrate a debilitating preoccupation with one or more perceived defects, often marked by poor insight or delusional convictions. Multiple studies have suggested that selective serotonin reuptake inhibitors and various cognitive behavioral therapy modalities are effective first-line treatments in decreasing BDD severity, relieving depressive symptoms, restoring insight, and increasing quality of life. Selective serotonin reuptake inhibitors have also recently been shown to be effective for relapse prevention. This review provides a comprehensive summary of the current understanding of BDD, including its clinical features, epidemiology, genetics, and current treatment modalities. Additional research is needed to fully elucidate the relationship between BDD and comorbid illnesses such as obsessive-compulsive-related disorders and depression and to develop therapies for refractory patients and those who have contraindications for pharmacological intervention.

KW - BDD

KW - Body dysmorphic disorder

KW - CBT

KW - Cognitve behavioral therapy

KW - TMS

KW - Transcranial magnetic stimulation

UR - http://www.scopus.com/inward/record.url?scp=85044719832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044719832&partnerID=8YFLogxK

U2 - 10.12688/f1000research.13700.1

DO - 10.12688/f1000research.13700.1

M3 - Review article

VL - 7

JO - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 361

ER -